A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy - CAPDOV

Trial Profile

A phase I study of TKI258 and capecitabine in patients with advanced pancreatic cancer and treatment failure after first-line chemotherapy - CAPDOV

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Dovitinib (Primary) ; Capecitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms CAPDOV
  • Most Recent Events

    • 17 Mar 2015 Status changed from recruiting to discontinued.
    • 23 Jan 2015 Status changed from not yet recruiting to recruiting.
    • 23 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top